Identification of Motivators and Barriers Impacting Successful Food Introduction or Reintroduction after Negative Oral Food Challenges

TY - JOUR

T1 - Identification of Motivators and Barriers Impacting Successful Food Introduction or Reintroduction after Negative Oral Food Challenges

AU - Ditlof, Christina M

AU - Hummel, Roxanne H

AU - Wong, Sam

AU - Li, Carmen H

AU - Alexanian-Farr, Mara

AU - Zahrebelny, Slavka O

AU - Hoang, Jennifer A

AU - Hung, Lisa

AU - Upton, Julia E M

AU - Atkinson, Adelle R

AU - Asper, Maria

AU - Hummel, David

AU - Eiwegger, Thomas

N1 - Funding Information: This work has been supported by unrestricted grants from the Food Allergy and Anaphylaxis Program at the Hospital for Sick Children. Conflicts of interest: J. E. M. Upton reports grants/research support from DBV Technologies, Regeneron, CIHR, ALK-Abelló, and the SickKids Food Allergy and Anaphylaxis Program; served on the advisory board for Pfizer, Kaleo, Bausch Health, and Food Allergy Canada; received an in-kind drug donation from Novartis; and other services for Astra-Zeneca, all outside the current work. T. Elwegger reports to act as a local principal investigator for company-sponsored trials by DBV Therapeutics, and Greer Stallergens; as a subinvestigator for Regeneron and ALK-Abelló; is co-investigator or scientific lead in 3 investigator-initiated oral immunotherapy trials supported by the SickKids Food Allergy and Anaphylaxis Program; serves as an associate editor for Allergy; his laboratory received unconditional/in-kind contributions from Macro Array Diagnostics and an unrestricted grant from ALK-Abelló; holds advisory board roles for ALK-Abelló, VAMED, Nutricia/Danone, and Aimmune; and reports lecture fees from Novartis, ThermoFisher, Nutricia/Danone, Aimmune, and ALK-Abelló. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: This work has been supported by unrestricted grants from the Food Allergy and Anaphylaxis Program at the Hospital for Sick Children. Funding Information: Conflicts of interest: J. E. M. Upton reports grants/research support from DBV Technologies, Regeneron, CIHR, ALK-Abelló, and the SickKids Food Allergy and Anaphylaxis Program; served on the advisory board for Pfizer, Kaleo, Bausch Health, and Food Allergy Canada; received an in-kind drug donation from Novartis; and other services for Astra-Zeneca, all outside the current work. T. Elwegger reports to act as a local principal investigator for company-sponsored trials by DBV Therapeutics, and Greer Stallergens; as a subinvestigator for Regeneron and ALK-Abelló; is co-investigator or scientific lead in 3 investigator-initiated oral immunotherapy trials supported by the SickKids Food Allergy and Anaphylaxis Program; serves as an associate editor for Allergy; his laboratory received unconditional/in-kind contributions from Macro Array Diagnostics and an unrestricted grant from ALK-Abelló; holds advisory board roles for ALK-Abelló, VAMED, Nutricia/Danone, and Aimmune; and reports lecture fees from Novartis, ThermoFisher, Nutricia/Danone, Aimmune, and ALK-Abelló. The rest of the authors declare that they have no relevant conflicts of interest.

PY - 2023/6

Y1 - 2023/6

UR - https://www.scopus.com/pages/publications/85152692160

U2 - 10.1016/j.jaip.2023.03.040

DO - 10.1016/j.jaip.2023.03.040

M3 - Journal article

C2 - 36997121

SN - 2213-2198

VL - 11

SP - 1969-1971.e2

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

IS - 6

ER -